Skip to main content
. Author manuscript; available in PMC: 2021 Nov 5.
Published in final edited form as: Cell Stem Cell. 2020 Aug 20;27(5):748–764.e4. doi: 10.1016/j.stem.2020.07.021

Figure 1. R/R LSCs Have Increased Nicotinamide Metabolism.

Figure 1.

(A) Principal-component analysis of de novo and R/R LSCs generated using MetaboAnalyst 4.0. AML specimens used in this analysis include AML1–AML9 and AML14–AML16.

(B) Heatmap of amino acids levels in de novo and R/R LSCs. AML specimens used in this analysis include AML1–AML9 and AML14–AML16.

(C) Amino acids levels in paired de novo and relapsed LSCs. AML specimens used in this analysis include AML17–AML20.

(D) Nicotinamide levels in de novo and R/R LSCs. AML specimens used in this analysis include AML1–AML9 and AML14–AML20. The left graph represents nicotinamide levels in unpaired specimens, and the right graph represents nicotinamide levels in paired specimens.

(E) NAD+ levels in paired de novo and relapsed LSCs and AML blasts (non-LSCs). AML specimens used in this analysis include AML17–AML21.

(F) Levels of SIL nicotinamide in de novo and R/R LSCs 12 h after [13C3,15N] nicotinamide incubation determined by mass spectrometry. AML2 and AML5 were used in this analysis.

(G) Levels of SIL NAD+ from nicotinamide in de novo and R/R LSCs 12 h after [13C3,15N] nicotinamide incubation determined by mass spectrometry. AML2 and AML5 were used in this analysis.

(H) Ratio of SIL NAD+/nicotinamide in de novo and R/R LSCs 12 h after [13C3,15N] nicotinamide incubation. AML2 and AML5 were used in this analysis. Statistical significance was determined using Student’s t test (B, D, F–H) or a paired Student’s t test (E). *p < 0.05, **p < 0.01, ***p < 0.005 ****p < 0.001.